Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.
New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...
MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...
While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, ...
Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...
The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.
Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited ...
Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.
Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.